Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) PT at $16.80

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has earned an average recommendation of “Hold” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $16.80.

Several analysts have recently commented on HCM shares. Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings cut shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Bank of America reduced their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Finally, Morgan Stanley set a $13.60 target price on shares of HUTCHMED in a research note on Thursday, May 28th.

Institutional Trading of HUTCHMED

Institutional investors and hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. grew its position in HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of HUTCHMED by 5.9% in the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after buying an additional 1,209 shares during the period. Crossmark Global Holdings Inc. lifted its position in shares of HUTCHMED by 3.3% in the fourth quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock worth $700,000 after purchasing an additional 1,680 shares in the last quarter. State Street Corp increased its stake in shares of HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of HUTCHMED by 3.0% during the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after purchasing an additional 3,900 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Trading Up 2.6%

HCM stock opened at $10.96 on Wednesday. HUTCHMED has a one year low of $10.40 and a one year high of $19.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96. The company has a fifty day moving average of $13.11 and a 200-day moving average of $13.93.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.